                                                                                                                                   I




                                  113TH CONGRESS
                                     1ST SESSION                          H. R. 486
                                        To amend the Federal Food, Drug, and Cosmetic Act to incentivize the
                                                      development of abuse-deterrent drugs.




                                                IN THE HOUSE OF REPRESENTATIVES
                                                                FEBRUARY 4, 2013
                                  Mr. KEATING (for himself, Mr. ROGERS of Kentucky, Mr. RAHALL, Mr.
                                      LYNCH, Ms. HANABUSA, and Mr. BUCHANAN) introduced the following
                                      bill; which was referred to the Committee on Energy and Commerce




                                                                            A BILL
                                        To amend the Federal Food, Drug, and Cosmetic Act to
                                         incentivize the development of abuse-deterrent drugs.
                                    1              Be it enacted by the Senate and House of Representa-
                                    2 tives of the United States of America in Congress assembled,
                                    3     SECTION 1. SHORT TITLE.
                                    4              This Act may be cited as the ‘‘Stop Tampering of
                                    5 Prescription Pills Act of 2013’’.
                                    6     SEC. 2. ABUSE-DETERRENT TECHNOLOGY.

                                    7              (a) DEFINITION.—Section 201 of the Federal Food,
                                    8 Drug, and Cosmetic Act (21 U.S.C. 321) is amended by




                                    9 adding at the end the following:
                                                                                             2
                                    1              ‘‘(ss) The term ‘abuse-deterrent drug’ means a drug
                                    2 that—
                                    3                        ‘‘(1) contains as an active moiety a controlled
                                    4              substance that has been classified as opium, an opi-
                                    5              ate, or a derivative thereof, as such terms are de-
                                    6              fined or used in section 102 of the Controlled Sub-
                                    7              stances Act;
                                    8                        ‘‘(2) has been formulated for oral administra-
                                  109              tion; and ‘‘(3)(A)         exhibits           physicochemical                   properties
                                  11               (demonstrated by in vitro, in vivo, or other testing,
                                  12               or some combination thereof, as determined appro-
                                  13               priate by the Secretary) that make product manipu-
                                  14               lation significantly more difficult or ineffective in al-
                                  15               tering the characteristics of the drug for purposes of
                                  16               misuse or abuse when compared to drugs without
                                  17               such properties; or
                                  18                         ‘‘(B) contains one or more additional active or
                                  19               inactive ingredients that are intended to deter abuse
                                  20               through potential pharmacological effects, the effec-
                                  21               tiveness of which has been demonstrated by at least
                                  22               one adequate and well-controlled investigation.’’.
                                  23               (b) REQUIRED INFORMATION                                  IN    APPLICATION          FOR
                                  24 APPROVAL                   OF    BRAND NAME DRUGS.—Section 505(b) of





                                              •HR 486 IH

                                                                                             3
                                    1 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
                                    2 355(b)) is amended by adding at the end the following:
                                    3                        ‘‘(7) ABUSE-DETERRENT                           DRUGS.—If             an appli-
                                    4              cation submitted under this subsection is potentially
                                    5              subject to refusal under subsection (d)(7), the appli-
                                    6              cation shall include such information as the Sec-
                                    7              retary determines necessary to demonstrate that the
                                    8              application is not subject to such refusal.’’.
                                    9              (c) APPROVAL               OF     NEW BRAND NAME DRUGS.—Sec-
                                  10 tion 505(d) of the Federal Food, Drug, and Cosmetic Act
                                  11 (21 U.S.C. 355(d)) is amended—
                                  12                         (1) by inserting ‘‘(7)(A) such drug has been
                                  13               formulated for oral administration; (B) such drug
                                  14               contains as an active moiety a controlled substance
                                  15               that has been classified as opium, an opiate, or a de-
                                  16               rivative thereof, as such terms are defined or used
                                  17               in section 102 of the Controlled Substances Act; (C)
                                  18               such drug is not an abuse-deterrent drug; and (D)
                                  19               the Secretary has previously approved pursuant to
                                  20               an application submitted under subsection (b) or (j)
                                  21               a drug that (i) contains the same active moiety; (ii)
                                  22               is an abuse-deterrent drug, and (iii) has not been
                                  23               discontinued from marketing; or’’ after ‘‘(6) the ap-
                                  24               plication failed to contain the patent information




                                  25               prescribed by subsection (b); or’’;
                                              •HR 486 IH

                                                                                             4
                                    1                        (2) by striking ‘‘(7) based on fair’’ and insert-
                                    2              ing ‘‘(8) based on fair’’;
                                    3                        (3) by striking ‘‘clauses (1) through (6)’’ and
                                    4              inserting ‘‘paragraphs (1) through (7)’’; and
                                    5                        (4) by inserting ‘‘The Secretary may issue an
                                    6              order approving an application, even if paragraph
                                    7              (7) applies, upon a finding that paragraphs (1)
                                    8              through (6) and paragraph (8) do not apply and
                                    9              that such approval is necessary either to prevent or
                                  10               alleviate a drug shortage or to otherwise address a
                                  11               significant unmet public health need.’’ before ‘‘As
                                  12               used in this subsection and subsection (e)’’.
                                  13               (d) GENERIC DRUGS.—Section 505(j) of the Federal
                                  14 Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)) is
                                  15 amended—
                                  16                         (1) in paragraph (2)—
                                  17                                  (A) subparagraph (A)—
                                  18                                         (i) in clause (vii), by striking ‘‘and’’ at
                                  19                                  the end;
                                  20                                         (ii) in clause (viii), by striking the pe-
                                  21                                  riod at the end and inserting ‘‘; and’’;
                                  22                                         (iii) by inserting after clause (viii) the
                                  23                                  following:
                                  24                         ‘‘(ix) if the listed drug is an abuse-deterrent




                                  25               drug due to its physicochemical properties, informa-
                                              •HR 486 IH

                                                                                             5
                                    1              tion from comparative in vitro, in vivo, or other test-
                                    2              ing, or some combination thereof, as appropriate
                                    3              based on the type of data submitted for the listed
                                    4              drug, that demonstrates the new drug resists manip-
                                    5              ulation or the effect of manipulation to a degree at
                                    6              least comparable to the listed drug.’’; and
                                    7                                        (iv) in the continuation text at the
                                    8                                 end of the subparagraph, by striking
                                    9                                 ‘‘clauses (i) through (viii)’’ and inserting
                                  10                                  ‘‘clauses (i) through (ix)’’;
                                  11                                  (B) in subparagraph (C)—
                                  12                                         (i) in clause (i), by striking ‘‘or’’ at
                                  13                                  the end;
                                  14                                         (ii) in clause (ii), by striking the pe-
                                  15                                  riod at the end and inserting ‘‘; or’’; and
                                  16                                         (iii) by adding at the end the fol-
                                  17                                  lowing:
                                  18                         ‘‘(iii) that the listed drug is an abuse-deterrent
                                  19               drug and one or more of the new drug’s active
                                  20               moieties differ in any material respect (in amount or
                                  21               otherwise) from those of the listed drug.’’;
                                  22                         (2) in paragraph (5), by adding at the end the
                                  23               following:
                                  24               ‘‘(G) If a drug has been approved pursuant to an ap-




                                  25 plication submitted under paragraph (2), and thereafter
                                              •HR 486 IH

                                                                                             6
                                    1 the listed drug referred to in the application becomes an
                                    2 abuse-deterrent drug, the drug so approved shall not be
                                    3 considered to be bioequivalent to, or to have the same
                                    4 therapeutic effect as, the listed drug (as described in para-
                                    5 graph (2)(A)(iv)) unless and until the drug so approved
                                    6 has been found by the Secretary to meet the requirements
                                    7 of paragraph (2)(A)(ix).’’; and
                                    8                        (3) in paragraph (6)—
                                    9                                 (A) by striking ‘‘(6) If a drug’’ and insert-
                                  10                         ing ‘‘(6)(A) If a drug’’;
                                  11                                  (B) by striking ‘‘(A) for the’’ and inserting
                                  12                         ‘‘(i) for the’’;
                                  13                                  (C) by striking ‘‘(B) if the’’ and inserting
                                  14                         ‘‘(ii) if the’’; and
                                  15                                  (D) by adding at the end the following:
                                  16               ‘‘(B) For purposes of this paragraph and paragraph
                                  17 (7)(C), a withdrawal or suspension of a drug formulated
                                  18 for oral administration shall be considered to have been
                                  19 for safety or effectiveness reasons if—
                                  20                         ‘‘(i) the approval of a listed drug, which is not
                                  21               an abuse-deterrent drug, is withdrawn or suspended,
                                  22               or a listed drug, which is not an abuse-deterrent
                                  23               drug, is withdrawn from sale; and





                                              •HR 486 IH

                                                                                             7
                                    1                        ‘‘(ii) the Secretary has previously approved pur-
                                    2              suant to an application under subsection (b) a drug
                                    3              that—
                                    4                                 ‘‘(I) is in the same dosage form;
                                    5                                 ‘‘(II) contains the same controlled sub-
                                    6                        stance as an active moiety;
                                    7                                 ‘‘(III) is an abuse-deterrent drug; and
                                    8                                 ‘‘(IV) has not been discontinued from mar-
                                    9                        keting.’’.
                                  10               (e)       WITHDRAWAL                      OF      PREVIOUSLY                    APPROVED
                                  11 BRAND NAME                       AND         GENERIC DRUGS.—Section 505(e) of
                                  12 the Federal Food, Drug, and Cosmetic Act (21 U.S.C.
                                  13 355(e)) is amended—
                                  14                         (1) by inserting ‘‘or (6)(A) the drug contains as
                                  15               an active moiety a controlled substance that has
                                  16               been classified as opium, an opiate, or a derivative
                                  17               thereof, as such terms are defined or used in section
                                  18               102 of the Controlled Substances Act; (B) the drug
                                  19               is formulated for oral administration; (C) the drug
                                  20               is not an abuse-deterrent drug; and (D) the Sec-
                                  21               retary has previously approved pursuant to an appli-
                                  22               cation submitted under subsection (b) or (j) a drug
                                  23               that contains the same active moiety, is an abuse-de-
                                  24               terrent drug, and has not been discontinued from




                                  25               marketing’’ before ‘‘: Provided,’’; and
                                              •HR 486 IH

                                                                                             8
                                    1                        (2) by adding at the end the following: ‘‘The
                                    2              Secretary may waive the application of paragraph
                                    3              (6) of the first sentence of this subsection in the
                                    4              case of a drug intended for use in a special needs
                                    5              population. In withdrawing (under paragraph (6) of
                                    6              the first sentence of this subsection) the approval of
                                    7              an application with respect to any drug, the Sec-
                                    8              retary shall, on a case-by-case basis, delay the effec-
                                    9              tive date of such withdrawal for a period deemed
                                  10               sufficient by the Secretary to give the sponsor an op-
                                  11               portunity to obtain approval under this section for
                                  12               a formulation of the drug meeting the criteria de-
                                  13               scribed in paragraph (2) of the definition of a
                                  14               ‘abuse-deterrent drug’ in section 201(ss).’’.
                                  15               (f) LISTED DRUGS.—Section 505(j)(7) of the Federal
                                  16 Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(7)) is
                                  17 amended by adding at the end the following:
                                  18               ‘‘(D) Beginning 60 days after the date of the enact-
                                  19 ment of the Stop Tampering of Prescription Pills Act of
                                  20 2013, the Secretary shall—
                                  21                         ‘‘(i) include in the list under subparagraph (A)
                                  22               a list of each drug or category of drugs which the
                                  23               Secretary has found to be abuse-deterrent drugs;
                                  24               and





                                  25                         ‘‘(ii) update the list under subparagraph (A)—


                                              •HR 486 IH

                                                                                             9
                                    1                                 ‘‘(I) to remove from the list of abuse-deter-
                                    2                        rent drugs any drug the Secretary later deter-
                                    3                        mines is not an abuse-deterrent drug; and
                                    4                                 ‘‘(II) as required by subparagraph (C) to
                                    5                        reflect the application of paragraph (6)(B) to
                                    6                        drugs that are withdrawn or suspended.’’.
                                              •HR 486 IH                                   Æ
